Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DS-9606a |
| Synonyms | |
| Therapy Description |
DS-9606a is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting CLDN6 linked to the cytotoxic agent pyrrolobenzodiazepine, which potentially induces killing of CLDN6-expressing tumor cells (Ann Oncol (2024) 35 (Suppl_2): S488 - S489, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DS-9606a | DS9606a|DS 9606a|DS9606|DS 9606|DS-9606 | CLDN6 Antibody 10 | DS-9606a is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting CLDN6 linked to the cytotoxic agent pyrrolobenzodiazepine, which potentially induces killing of CLDN6-expressing tumor cells (Ann Oncol (2024) 35 (Suppl_2): S488 - S489, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05394675 | Phase I | DS-9606a | A Study of DS-9606a in Patients With Advanced Solid Tumors | Active, not recruiting | USA | GBR | 0 |